Autopsy report · NCT07375212

VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure

“Change in Sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

Prisma Health-Upstate

Sponsor type

University, hospital or other

Conditions

Heart Failure Congestive

Interventions

Bumetanide, intranasal 4mg

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Genetic, Neurophysiological and Psychological Predictive Factors of Chronic Neuropathic Pain After Surgery for Breast Cancer
  “change of sponsor” (98% match in meaning)
• Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy
  “Sponsor change” (96% match in meaning)
• POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)
  “Change in Sponsor strategy” (87% match in meaning)
• Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
  “sponsor strategy change” (84% match in meaning)
• Effects of Dietary Supplements on Nail and Hair Health
  “Strategic change by sponsor” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.